# AstraZeneca’s Tagrisso with chemo improved PFS in lung cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-tagrisso-with-chemo-improved-pfs-in-lung-cancer/4121119079
- Published: 2023-05-17T08:08:32+01:00
- Author: Amilia Stone

Positive high-level results from the FLAURA2 Phase III trial showed **[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Tagrisso_ (osimertinib) in combination with chemotherapy demonstrated a statistically
significant and clinically meaningful improvement in progression-free survival (
PFS) compared to _Tagrisso_ alone for patients with locally advanced (Stage IIIB-
IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) 
non-small cell lung cancer (NSCLC).

Safety results and discontinuation rates due to adverse events were consistent with
the established profiles of each medicine. At the time of this analysis, the overall
survival (OS) data were immature and will be formally assessed at a subsequent analysis.

Each year, there are an estimated 2.2 million people diagnosed with lung cancer 
globally with 80-85% of patients diagnosed with NSCLC, the most common form of lung
cancer.^(1-3) Approximately 70% of people are diagnosed with advanced NSCLC. Additionally,
about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia
have EGFRm NSCLC.^(4-6)

> **Pasi A. Jänne, MD, PhD, medical oncologist at Dana-Farber Cancer Institute and
> principal investigator for the FLAURA2 trial, said**: “As the global standard 
> of care for EGFR-mutated non-small cell lung cancer, osimertinib monotherapy has
> transformed the treatment landscape allowing many patients the opportunity to 
> achieve improved survival. FLAURA2 provides compelling evidence that the addition
> of chemotherapy to osimertinib can provide a new option for patients and clinicians
> that further improves outcomes compared to osimertinib alone and as such, can 
> further delay treatment resistance and disease progression.”

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said**:“
> These significant FLAURA2 results show _Tagrisso_ has the potential to offer patients
> in the first-line setting a new treatment option that can extend the time they
> live without their disease progressing. This meaningfully builds on successive
> trials which have demonstrated improved clinical benefit with _Tagrisso_ in patients
> with EGFR-mutated lung cancer.”​

The data will be presented at a forthcoming medical meeting and shared with global
health authorities.

These results add to the extensive body of evidence for _Tagrisso_ in EGFRm NSCLC,
which has improved patient outcomes in both early-stage disease in the ADAURA Phase
III trial and late-stage disease in the FLAURA Phase III trial. _Tagrisso_ has also
shown proven clinical activity in treating central nervous system (CNS) metastases
across settings. 

As part of AstraZeneca’s ongoing commitment to treating patients as early as possible
in lung cancer, _Tagrisso_ is also being investigated in unresectable NSCLC in the
pivotal LAURA Phase III trial, with results expected later this year.

Share on:
